DiaMedica Therapeutics (DMAC) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kamada (KMDA) has outperformed DiaMedica Therapeutics (DMAC) over the past year, gaining 18.6% versus a gain of 16.5%. Over five years, DMAC leads with a +94.9% price change compared with +49.7% for KMDA. Kamada is the larger company by market cap ($445.2 million vs $418.5 million), about 1.1 times the size.
Kamada pays a dividend yielding 3.24%, while DiaMedica Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMAC | KMDA |
|---|---|---|
| Share price | $7.76 | $7.72 |
| Market cap | $418.46M | $445.24M |
| 1-day change | -2.88% | -2.22% |
| YTD return | +0.38% | +11.76% |
| 1-year return | +16.47% | +18.65% |
| 5-year return | +94.88% | +49.72% |
| P/E ratio (TTM) | — | 20.30 |
| Forward P/E | — | 13.38 |
| EPS (TTM) | $-0.72 | $0.38 |
| Dividend yield | 0.00% | 3.24% |
| Annual dividend | $0.00 | $0.25 |
| 52-week high | $10.42 | $9.35 |
| 52-week low | $5.25 | $6.55 |
| Distance from 52-week high | -25.52% | -17.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +99.74% | +74.98% |
| Average volume | 176.44K | 118.04K |
| Shares outstanding | 53.93M | 57.71M |
| Employees | 35 | 462 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Kamada offers a meaningfully higher dividend yield (3.24% vs 0.00%).
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
DMAC vs KMDA FAQ
Which is bigger, DiaMedica Therapeutics or Kamada?
Kamada (KMDA) is larger, with a market capitalization of $445.24M compared with $418.46M for DiaMedica Therapeutics (DMAC).
Which stock has performed better over the past year, DMAC or KMDA?
KMDA returned +18.65% over the past 12 months, compared with +16.47% for DMAC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, DiaMedica Therapeutics or Kamada?
Kamada pays a dividend yielding 3.24%, while DiaMedica Therapeutics does not currently pay a regular dividend.
Are DiaMedica Therapeutics and Kamada in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.